Confirmed Keynotes include:

"New Directions for the Prevention and Reversal of Neurodegeneration" by Prof. Dr. Daniel Alkon
​CSO, Neurotrope BioScience

"Transforming Translational Neuroscience" by Michael D. Ehlers
Group SVP, Head, BioTherapeutics R&D, CSO, Neuroscience & Pain, Cambridge & Boston Site Head, Pfizer Inc.​

“Reinventing the Treatment of Dementia: A New Paradigm”​ by Vivek Ramaswamy
Chief Executive Officer, Axovant Sciences

Confirmed Speakers & Chairs include:

Andrew Singleton, Laboratory Chief, National Institute on Aging NIH
Barry Kenny, Chief Business Officer, Heptares Therapeutics
Bavani Shankar, ‎Director, Business Development, AstraZeneca Neuroscience iMed
Beth Jacobs, Managing Partner, Excellentia Global Partners
Bob Silverman, Head of Externalized Drug Discovery Partnering, Roche Innovation Center
Brian Hagerty, Senior Director, Capital Markets, New York Stock Exchange
Bruce Leuchter, Managing Director, PJT Partners
Carlos Buesa, CEO, Oryzon Genomics
Charles Duncan, Managing Director, Senior Research Analyst, Biotechnology, Piper Jaffray
Daniel Alkon, CSO, Neurotrope, Inc.
David Baker, Chief Commerical Officer, Alcobra Ltd.
Ed Mascioli, Venture Partner, SV Life Science Advisors
Elemer Piros, Senior Biotechnology Analyst, ROTH Capital Partners
Emer Leahy, President and CEO, PsychoGenics, Inc.
Eric Schaeffer, Senior Director Neuroscience External Innovation, Johnson & Johnson             
Eric Siemers, Distinguished Medical Fellow, Eli Lilly & Co.
Ginger Johnson, Vice President, Defined Health
Gerald Commissiong, President & CEO, Amarantus BioScience Holdings, Inc.
Hendrik Liebers, CFO, Probiodrug AG
Jak Knowles, Managing Director and Vice President Medical and Scientific Affairs, CureDuchenne Ventures
Jeffrey Davis, COO, Abeona Therapeutics, Inc.
Jennifer Farmer, Executive Director, Friedreich's Ataxia Research Alliance
Jerry McLaughlin, President & CEO, AgeneBio, Inc.
Jim Ray, Institute Head, Neuroscience, The Neurodegeneration Consortium, MD Anderson
Joel  Braunstein, CEO, C2N Diagnostics
John Kaiser, Chief Business Officer, Cerecor, Inc.
John Renger, ‎ Associate Vice President, Target Acceleration & Translational Capabilities, Neuroscience, Merck
Kathryn Gregory, Executive Director, Licensing & Business Development, Purdue Pharma L.P.
Kees Been, Chief Executive Officer, Lysosomal Therapeutics
Kiran Reddy, Venture Partner, Clarus Ventures, LLC
Liam Ratcliffe, Managing Director, New Leaf Venture Partners
Mark Day, Executive Director, Head of External Research & Scouting, Alexion Pharmaceuticals, Inc.
Mark Mintun, President & Chief Medical Officer, Avid Radiopharmaceuticals, Inc.
Martin Heidecker, Managing Director, Boehringer Ingelheim Venture USA, Inc.
Maurice Zauderer, President and Chief Executive Officer, Vaccinex, Inc.
Maxim Jacobs, Senior Healthcare Analyst, Edison Investment Research
Murali Gopalakrishnan, Senior Director, Search & Evaluation Neuroscience, AbbVie
Nessan Bermingham, Chief Executive Officer, Intellia Therapeutics, Inc.
Paul Thibodeau, Senior Director, Business Development, Teva Pharmaceutical Industries Ltd.
Peter Thompson, Venture Partner, OrbiMed Advisors, LLC
PJ Anand, Chief Executive Officer, Alcyone Lifesciences, Inc.
​Reinhard Gabathuler, Chief Scientist, biOasis Technologies, Inc.
Robert Silverman, Head External Drug Discovery Partnering, Roche
Ronald Notvest, SVP Commercial Planning and Development, Tonix Pharmaceuticals Holding Corp.     ​
Ryan Westphal, ‎ Sr. Director, Neuroscience Search & Evaluation, Eli Lilly and Co.
Stacie Weninger, Executive Director, F-Prime Biomedical Research Initiative
Stephen Webster, Chief Executive Officer, Spark Therapeutics, Inc.
Steve Dickman , Chief Executive Officer, CBT Advisors
Steven Perrin, CEO and CSO, ALS Therapy Development Inst. 
Thomas Heffner, Executive Director of Worldwide Business Development, Pfizer, Inc.  
Timo Veromaa, President and CEO, Biotie Therapies Corp.
Todd Sherer, Chief Executive Officer, Michael J. Fox Foundation
Vivek Ramaswamy, Chief Executive Officer, Axovant Sciences, Inc.